Kumaraguru Raja
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
13
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $4.04 | +98.02% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $4.37 | +2,188.33% | 2 | May 30, 2024 | |
| HEPA Hepion Pharmaceuticals | Downgrades: Hold | n/a | $0.63 | - | 1 | Dec 7, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $6.06 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $1.01 | +14,825.37% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $5.30 | +183.02% | 1 | Jun 29, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $16.96 | +430.66% | 1 | Dec 9, 2022 | |
| VERU Veru Inc. | Maintains: Buy | $29 → $31 | $0.73 | +4,125.16% | 2 | May 18, 2022 | |
| DRMA Dermata Therapeutics | Initiates: Buy | $3,360 | $1.22 | +275,739.42% | 1 | Sep 21, 2021 | |
| ONCT Oncternal Therapeutics | Initiates: Buy | $320 | $1.48 | +21,521.62% | 1 | Mar 30, 2021 |
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $4.04
Upside: +98.02%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $4.37
Upside: +2,188.33%
Hepion Pharmaceuticals
Dec 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.63
Upside: -
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $6.06
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $1.01
Upside: +14,825.37%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $5.30
Upside: +183.02%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $16.96
Upside: +430.66%
Veru Inc.
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.73
Upside: +4,125.16%
Dermata Therapeutics
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $1.22
Upside: +275,739.42%
Oncternal Therapeutics
Mar 30, 2021
Initiates: Buy
Price Target: $320
Current: $1.48
Upside: +21,521.62%